Contrary to this, however, in the present study, we demonstrated the unusual significant (p<0.05) down-regulation of CXCL12 at mRNA levels in COAD patients of different clinicopathological features including different races, cancer stages, genders, age groups, and body weights as compared to the normal controls. This evidence concerns the gene CXCL12 and colon adenocarcinoma.